Daily Roundup

AYA.ASX XRG.ASX NST.ASX EYE.ASX CSL.ASX

Artrya Ltd is making solid headway with its Salix® AI platform in the U.S. market. The medical technology company reported that key customers, including Northeast Georgia Health System, are set to go live with the platform in July. Meanwhile, validation work on Salix® Coronary Flow is nearing completion, with an FDA submission expected soon. The company has also kicked off the SAPPHIRE Study and advanced its Clinical Advisory Board formation, strengthening its clinical credentials stateside. With a pro forma cash position of $74.0 million, Artrya is well-positioned to accelerate commercialization with an increasingly repeatable deployment model.

XReality Group is firing on all cylinders. The augmented reality company posted a 46% jump in quarterly cash receipts to $6.9 million, while full-year net operating cash flow surged 88% to $5.8 million. The customer base has nearly doubled year-over-year to 118 worldwide, with 108 of those in the U.S. Annual Recurring Revenue climbed to $8.0 million, up 69% from last year. On the business development front, XRG secured its first European contract with the Swedish Armed Forces, valued at approximately $0.45 million, and successfully wrapped up a $5.6 million U.S. Department of Defense project on time and on budget.

Northern Star Resources delivered a solid quarter operationally. The gold miner sold 433,482 ounces at an all-in sustaining cost of A$2,651 per ounce, generating a net mine cash flow of A$1,179 million across its production centers. The company's flagship KCGM Mill Expansion Project is now in the commissioning phase, with Stage 1 expected to ramp up in the first half of FY27. Northern Star also announced a leadership change, appointing Suresh Vadnagra as Managing Director and CEO, effective October 5, 2026. The company is guiding for FY26 cash earnings of A$2,860-2,950 million, with full FY27 guidance and an update on the Hemi Project Final Investment Decision coming on August 20.

Nova Eye Medical is turning a corner financially. The eye care company reported FY26 sales of US$23.7 million, up 26% year-over-year, with sales excluding China climbing 29% to US$22.7 million. More impressively, the company achieved positive EBITDA of US$0.14 million in the second half of the year, beating guidance. Cash burn has also tightened significantly, with group cash outflow from operations dropping to just A$0.2 million for the quarter. Looking ahead, Nova Eye is guiding for FY27 sales between US$26 million and US$31 million, excluding China, with positive EBITDA expected to continue.

CSL Limited is investing in the future of plasma manufacturing. The biopharmaceutical giant announced it will begin clinical trials in mid-2027 for its Horizon 2 process at its Broadmeadows facility. The patented technology is designed to significantly boost immunoglobulin production from the same plasma base. CSL has already engaged with the FDA and EMA to gather the clinical evidence needed for regulatory approval, positioning the company to enhance operational efficiencies and expand production capacity.